glp-1-based treatments approved for weight loss 2025 GLP-1 Pipeline Update: August - Prime Therapeutics Emerging Weight Loss Drugs and

Description

Gut microbiota and immune system interactions: key role in systemic inflammation Different studies discovered that the inactivation of an inflammasomes component, NOD-like receptor family pyrin domaincontaining 6 (NLRP6) protein, in mice, determines the expansion of Prevotella spp

Plaintiffs lawyers contend that Ozempic was promoted to lower blood sugar and help patients lose weight by helping them curb appetite, but the risks to the stomach were understated or omitted entirely

A poll released Friday by KFF found that about 1 in 8 adults say they are currently taking a GLP-1 drug to treat a chronic disease, for weight loss or both an increase of 6% since May 2024

Joseph Rizzo, director of the neuro-ophthalmology service at Mass Eye and Ear, recognized this unusual pattern and initiated the comprehensive investigation that would reveal the medications vision risks